NCT02121418View on ClinicalTrials.gov

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 8, 2017

Study Completion Date

February 14, 2018

Conditions
Chronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeMyeloproliferative NeoplasmUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IV

DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (9)

59715

Bozeman Deaconess Hospital, Bozeman

98033

EvergreenHealth Medical Center, Kirkland

98052

Group Health Cooperative, Redmond

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

98274

Skagit Valley Hospital, Mount Vernon

98362

Olympic Medical Center, Port Angeles

98415

Multicare Health System, Tacoma

98801

Wenatchee Valley Hospital and Clinics, Wenatchee

99336

Kadlec Clinic Hematology and Oncology, Kennewick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02121418 - Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | Biotech Hunter | Biotech Hunter